张文宏:已看到漫漫长夜的曙光,关键是疫苗接种率和病死率控制得很低

2022-01-08 网络 网络

感染新冠病毒奥密克戎变异株后,生命健康受到的影响有多大?今天举行的光华科技公益论坛上,国家传染病医学中心主任、复旦大学附属华山医院感染科主任张文宏表示,一些自媒体说奥密克戎引发的是“大号流

感染新冠病毒奥密克戎变异株后,生命健康受到的影响有多大?今天举行的光华科技公益论坛上,国家传染病医学中心主任、复旦大学附属华山医院感染科主任张文宏表示,一些自媒体说奥密克戎引发的是“大号流感”,这是缺乏科学依据的,他研究奥密克戎感染者的医学影像后认为,这种变异株“会咬人”。一个国家和地区需要强大的免疫屏障和医疗资源,才能抵御奥密克戎的威胁。

“今天上午8点半,我还轻轻抚摸过奥密克戎的片子。”张文宏告诉听众,“自媒体说这个变异株引起的是‘大号流感’,这是不足为据的,我们复旦校友可不要人云亦云。”据介绍,奥密克戎是新冠病毒在人体免疫压力下的自然选择结果,“可以说,奥密克戎在与免疫系统斗争后赢了”。目前,这种首先在南非发现的变异株已肆虐全球,导致很多国家和地区的感染人数大幅上升。

张文宏认为,西方国家之所以在“硬闯”这波疫情,其底气主要来自疫苗,其效果有待进一步评估。目前,美国的新冠疫苗接种率接近70%,三针疫苗接种率是22%,所以大多数健康的年轻人有望平安“闯”过这波疫情,但免疫力低下的人群呢?前景不容乐观。英国近期每天新增确诊人数超过20万,但病死率没有明显上升。究其原因,是英国的新冠疫苗接种率达到80%,三针疫苗接种率超过50%,且尚未出现严重的医疗资源挤兑情况。

在亚洲,新加坡的两针及以上新冠疫苗接种率高达90%以上,目前病死率控制在非常低的水平。以色列近期每天新增确诊人数超过1万,但病死率也非常低,其主要原因也是疫苗接种率高,三针接种率达到50%。以色列政府规定,60岁以上老年人必须接种第三针疫苗。

“我们允许关于疫苗接种的争论,但要看到,疫苗在新冠疫情防控中的作用是不可低估的。”张文宏说,“如果我们不积极接种疫苗,筑起强大的免疫屏障,就会回到1918年那次全球疫情。”在他看来,虽然疫苗屏障没有完全防住新冠病毒的传播,但它已让病毒的毒性大幅下降,降低了感染者的病死率。

除了不断提高疫苗两针及以上的接种率,一个国家或地区还要确保医疗资源的充分供给,这样才能对免疫力低下的感染者进行充分救治。“如果医疗资源不够,奥密克戎是会‘咬人’的。”张文宏说,“我国各地都要确保医疗资源的充分和平等。”

在演讲结束前,他表示,“已看到漫漫长夜的曙光”。“世界何时重新开放?一是要筑起强大的免疫屏障,二是把病死率控制得很低。”

光华科技公益论坛举行前,举办了首届光华论坛暨复旦大学校友会光华生命健康分会成立仪式。中国科学院院士、复旦大学校长金力和中国科学院院士、中国科学院上海药物研究所研究员陈凯先为分会揭牌,陈凯先受聘为光华生命健康分会理事长。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677432, encodeId=296716e74320f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Thu Mar 03 00:51:47 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725208, encodeId=178e1e2520846, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Jul 03 10:51:47 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078681, encodeId=607f20e86813d, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 11 12:51:47 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258134, encodeId=2f48125813461, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Jan 10 09:51:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182414, encodeId=dab711824140b, content=期待长夜早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jan 09 06:55:02 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677432, encodeId=296716e74320f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Thu Mar 03 00:51:47 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725208, encodeId=178e1e2520846, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Jul 03 10:51:47 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078681, encodeId=607f20e86813d, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 11 12:51:47 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258134, encodeId=2f48125813461, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Jan 10 09:51:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182414, encodeId=dab711824140b, content=期待长夜早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jan 09 06:55:02 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-07-03 yangpeizhi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677432, encodeId=296716e74320f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Thu Mar 03 00:51:47 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725208, encodeId=178e1e2520846, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Jul 03 10:51:47 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078681, encodeId=607f20e86813d, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 11 12:51:47 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258134, encodeId=2f48125813461, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Jan 10 09:51:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182414, encodeId=dab711824140b, content=期待长夜早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jan 09 06:55:02 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-08-11 gous
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677432, encodeId=296716e74320f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Thu Mar 03 00:51:47 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725208, encodeId=178e1e2520846, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Jul 03 10:51:47 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078681, encodeId=607f20e86813d, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 11 12:51:47 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258134, encodeId=2f48125813461, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Jan 10 09:51:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182414, encodeId=dab711824140b, content=期待长夜早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jan 09 06:55:02 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1677432, encodeId=296716e74320f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Thu Mar 03 00:51:47 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725208, encodeId=178e1e2520846, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Jul 03 10:51:47 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078681, encodeId=607f20e86813d, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 11 12:51:47 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258134, encodeId=2f48125813461, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Jan 10 09:51:47 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182414, encodeId=dab711824140b, content=期待长夜早日过去, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Jan 09 06:55:02 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-09 学医无涯

    期待长夜早日过去

    0

相关资讯

张文宏上海纽约大学2021年毕业典礼致辞:世界仅有科学是不够的

上海纽约大学2021届本科生毕业典礼在上海东方艺术中心举行,庆祝近300名毕业生顺利完成四年学业。这也是学校自新冠肺炎疫情暴发以来首次举办线下毕业典礼。

张文宏论文被举报,复旦公布调查结果,不构成学术不端或学术不当行为

校学术规范委员会依据2017年《复旦大学学术规范实施条例(试行)》的有关程序开展调查核实工作,根据原上海医科大学1999年1月修订的《科研型博士研究生培养工作细则》,认定张文宏博士学位论文符合当年博士

Cell Res:张文宏发表论文,证实新冠疫苗加强针效果显著

截至目前,全世界累计确诊新冠病例超过2.5亿,导致超过500万人死亡。广泛的疫苗接种可以帮助建立对新冠肺炎的全体免疫力。

2021年11月30日简报:张文宏解读奥密克戎;新冠孤儿恐将影响人类几十年;南非医生证实感染Omicron患者极度疲劳,仅少数人发烧;

截至北京时间2021年11月30日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6230万例,新增422,682例,达到262,301,

张文宏:抗疫的**境界是让老百姓“没有感觉”

第三届进博会正在上海举行,今年的展览规模与往年相比进一步扩大。“大家一开始可能担心这么大的展会召开,会不会对防疫造成很大影响,但现在感觉就像往年一样。”复旦大学附属华山医院感染

超大城市将如何提升应对突发公共卫生事件能力?张文宏等这么说……

新冠肺炎疫情发生以来,公众对城市公共卫生安全有了更高期待。当前及未来五年,超大城市如何进一步筑牢公共卫生安全体系,提高针对突发传染病等公共卫生事件的应急处置能力?记者在北上广三地两会上进行了深入采访。